DRUG DEVELOPMENT PROCESS


INTRODUCTION

The drug development process is designed to ensure the innovative a new medicine are effective, safe and available professions in a student possible time.


Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery


It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug.






STEPS INVOLVED IN DRUG DEVELOPMENT PROCESS


Step 1 : Discovery and Development


Step 2 : Preclinical Research


Step 3 : Clinical Research


Step 4 : FDA Review


Step 5 : FDA Post-Market Safety Monitoring

Step 1 : Discovery and Development


  • New insights into a disease process that allow researchers to design a product to stop or reverse the effects of the disease.

  • Many tests of molecular compounds to find possible beneficial effects against any of a large number of diseases.

  • New technologies, such as those that provide new ways to target medical products to specific sites within the body or to manipulate genetic material.

  • How it is absorbed, distributed, metabolized, and excreted.

  • Its potential benefits and mechanisms of action.

  • The best dosage.

  • How it interacts with other drugs and treatments.

  • Its effectiveness as compared with similar drugs.

Step 2 : Preclinical Research

  • Before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. The two types of preclinical research are:

  • In vitro

  • In vivo

 These regulations set the minimum basic requirements for:

  • study conduct

  • personnel

  • facilities

  • equipment

  • written protocols

  • operating procedures

  • study reports

Usually, preclinical studies are not very large. However, these studies must provide detailed information on dosing and toxicity levels. After preclinical testing, researchers review their findings and decide whether the drug should be tested in people.

Step 3 : Clinical Research

While preclinical research answers basic questions about a drug’s safety, it is not a substitute for studies of ways the drug will interact with the human body. “Clinical research” refers to studies, or trials, that are done in people. As the developers design the clinical study, they will consider what they want to accomplish for each of the different Clinical Research Phases and begin the Investigational New Drug Process (IND), a process they must go through before clinical research begins.

On this page you will find information on:

Step 4 : FDA Review

Once FDA receives an NDA, the review team decides if it is complete. If it is not complete, the review team can refuse to file the NDA. If it is complete, the review team has 6 to 10 months to make a decision on whether to approve the drug. The process includes the following:

  • Each member of the review team conducts a full review of his or her section of the application. For example, the medical officer and the statistician review clinical data, while a pharmacologist reviews the data from animal studies. Within each technical discipline represented on the team, there is also a supervisory review.

  • The project manager assembles all individual reviews and other documents, such as the inspection report, into an “action package.” This document becomes the record for FDA review. The review team issues a recommendation, and a senior FDA official makes a decision.


Step 5 : FDA Post-Market Safety Monitoring

Even though clinical trials provide important information on a drug’s efficacy and safety, it is impossible to have complete information about the safety of a drug at the time of approval. Despite the rigorous steps in the process of drug development, limitations exist. Therefore, the true picture of a product’s safety actually evolves over the months and even years that make up a product’s lifetime in the marketplace. FDA reviews reports of problems with prescription and over-the-counter drugs, and can decide to add cautions to the dosage or usage information, as well as other measures for more serious issues.


REFERENCE

https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process

https://en.wikipedia.org/wiki/Drug_development

https://www.slideteam.net/drug-discovery-and-development-process.html



Student Name: Dhamodhiram A  

Student ID: 174/082023

Qualification: M.Sc., Biotechnology

e-Mail ID: dhamubiotech824@gmail.com







































Comments

Tutor said…
IGCP is an advanced Clinical Research training center in Hyderabad with ISO Certification. IGCP is a leading Clinical Research Training Institute in Hyderabad.

Popular Posts